Prospect News: News for Neopharmed Gentili SpA

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with N > Issuers starting with N, BK only > All stories on Neopharmed Gentili SpA > Stories on Neopharmed Gentili SpA, BK only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Neopharmed Gentili SpA

2/18/2025	BKHY	Fitch cuts Neopharmed notes
4/24/2024	BKHY	S&P rates Neopharmed notes B
3/25/2024	BKHY	Moody’s gives Neopharmed, notes B3
3/25/2024	BKHY	Fitch assigns Neopharmed B, notes B+
3/25/2024	BKHY	S&P rates Neopharmed Gentili, notes B

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.